Vanda Pharmaceuticals (VNDA) FCF Margin (2010 - 2026)

Vanda Pharmaceuticals has disclosed FCF Margin across 17 years of filings, most recently posting 97.53% for Q1 2026.

• FCF Margin for Q1 2026 came in at 97.53%, down 3042.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 58.45% (down 2995.0% YoY), and the FY2025 annual result was 51.1%, down 4293.0% from the prior year.
• FCF Margin came in at 97.53% for Q1 2026 at Vanda Pharmaceuticals, down from 51.59% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 50.8% in Q1 2023 to a low of 97.53% in Q1 2026.
• The 5-year median for FCF Margin is 8.8% (2023), against an average of 16.38%.
• Across the five-year window, FCF Margin soared 4421 bps in 2023 and tumbled 8304 bps in 2025, its largest moves.
• Vanda Pharmaceuticals' FCF Margin stood at 14.19% in 2022, then plunged by 162 bps to 8.8% in 2023, then jumped by 57 bps to 3.82% in 2024, then plunged by 1251 bps to 51.59% in 2025, then tumbled by 89 bps to 97.53% in 2026.
• The last three FCF Margin figures came in at 97.53% (Q1 2026), 51.59% (Q4 2025), and 56.5% (Q3 2025), per Business Quant data.